Cloxacillin: Difference between revisions
(general drug info) |
(adult dosing) |
||
Line 5: | Line 5: | ||
==Adult Dosing== | ==Adult Dosing== | ||
===Upper Respiratory Tract Infection=== | |||
* 250 mg PO q6hrs for 7-14 days | |||
===Pneumonia=== | |||
* 500 mg PO q6hrs for up to 21 days | |||
===Soft tissue/skin infection=== | |||
*500 mg PO q6hrs for 7 days or until 3 days after acute inflammation resolves | |||
==Pediatric Dosing== | ==Pediatric Dosing== |
Revision as of 02:06, 7 February 2016
General
- Type: Beta lactamase resistant penicillins
- Dosage Forms: 125 mg/5 ml oral powder, 250 mg, 500 mg
- Common Trade Names: Cloxapen, Dry Clox, Tegopen
Adult Dosing
Upper Respiratory Tract Infection
- 250 mg PO q6hrs for 7-14 days
Pneumonia
- 500 mg PO q6hrs for up to 21 days
Soft tissue/skin infection
- 500 mg PO q6hrs for 7 days or until 3 days after acute inflammation resolves
Pediatric Dosing
Special Populations
- Pregnancy Rating:
- Lactation:
- Renal Dosing
- Adult
- Pediatric
- Hepatic Dosing
- Adult
- Pediatric
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
- Mechanism of Action:
Antibiotic Sensitivities[1]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
See Also
Source
- ↑ Sanford Guide to Antimicrobial Therapy 2014